Teachers Advisors’s Matinas BioPharma MTNB Stock Holding History

Teachers Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,927	Closed	-$74K	–	3079
2018 Q1	$74K	Hold	1,927	–	–	﹤0.01%	2955
2017 Q4	$112K	Hold	1,927	–	–	﹤0.01%	2996
2017 Q3	$127K	Hold	1,927	–	–	﹤0.01%	3021
2017 Q2	$163K	Buy	+1,927	New	+$259K	﹤0.01%	3036

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Teachers Advisors's MTNB Position: Q2 2018 in Review

Teachers Advisors sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 1,927 shares — an estimated $74K sold.

Teachers Advisors first reported a position in MTNB in Q2 2017 and held it in 4 quarters. The position peaked at $163K in Q2 2017. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

Teachers Advisors reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
Teachers Advisors sold 1,927 Matinas BioPharma shares in Q2 2018, an estimated $74K.
Teachers Advisors first reported a position in Matinas BioPharma in Q2 2017 and held it in 4 quarters.
Teachers Advisors's Matinas BioPharma position peaked at $163K in Q2 2017.
39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on Teachers Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.